Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 13,275 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infusion Clear all
Terminated Phase 1 Interventional Results available

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

NCT03685344
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
Loncastuximab Tesirine and Durvalumab
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00003799
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

NCT01777165
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ABT-719, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 29, 2026, 4:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Recruiting Phase 3 Interventional

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

NCT05462704
View directory record Official record
Conditions
Iron Deficiency Anemia, Pregnancy
Interventions
Ferric derisomaltose, Ferrous sulfate
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT02566304
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 29, 2026, 4:48 PM EDT
Active, not recruiting Phase 1 Interventional

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500
View directory record Official record
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Carboplatin, Etoposide, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

NCT07414836
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BG-C0979, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tilavonemab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
57 Years to 88 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
CAR2 Anti-CD38 A2 CAR-T Cells
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

NCT00784147
View directory record Official record
Conditions
HIV
Interventions
Ibalizumab
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
28
States / cities
Beverly Hills, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Reevaluation Of Systemic Early Neuromuscular Blockade

NCT02509078
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Cisatracurium Besylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sleep and Healthy Aging Research on Depression for Younger Women

NCT03848715
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Endotoxin, Placebo
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
25 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

NCT01611935
View directory record Official record
Conditions
Traumatic Shock
Interventions
Vasopressin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Treatment of MS Fatigue

NCT03500289
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 29, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions
PT0511, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

NCT01186991
View directory record Official record
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02272790
View directory record Official record
Conditions
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions
Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

NCT04706923
View directory record Official record
Conditions
Adenovirus Infections, Cytomegalovirus Infection
Interventions
BCV
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

NCT01884688
View directory record Official record
Conditions
Asymptomatic Multiple Myeloma
Interventions
ENK Cell Infusion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

NCT00717340
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
tivozanib (AV-951) + paclitaxel
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

NCT04610320
View directory record Official record
Conditions
Allosensitization, Heart Transplant Failure and Rejection
Interventions
Daratumumab-SC
Drug
Lead sponsor
Ronald Witteles
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 29, 2026, 4:48 PM EDT
Active, not recruiting Phase 2 Interventional

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions
Obinutuzumab, Glofitamab
Drug
Lead sponsor
Reid Merryman, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 4:48 PM EDT
Completed Phase 4 Interventional

Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

NCT01791296
View directory record Official record
Conditions
Sleep Deprivation, Delirium
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Maisonneuve-Rosemont Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 29, 2026, 4:48 PM EDT